Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Vaccines|March 30, 2023
A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside MedicineSneha Bansode, Pawan Kumar Singh, Meenakshi Tellis, et al.Bioorganic & Medicinal Chemistry Letters|July 8, 2008
Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitorsJitendra A Sattigeri, Murugaiah M S Andappan, Kaushal Kishore, et al.Journal of Biomolecular Structure & Dynamics|April 25, 2020
Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main proteaseRakesh S Joshi, Shounak S Jagdale, Sneha B Bansode, et al.Bioorganic & Medicinal Chemistry Letters|November 9, 2005
WITHDRAWN: Derivatives of cis-1,2,3,6-tetrahydrophthalimide for the treatment of benign prostatic hyperplasiaP K S Sarma, Sanjay Jain, Neelima Sinha, et al.European Journal of Pharmacology|February 26, 2009
RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasiaKamna Nanda, Krishna S Naruganahalli, Suman Gupta, et al.Biotechnology Letters|August 17, 2006
Molecular cloning, stable expression and cellular localization of human alpha1-adrenergic receptor subtypes: effect of charcoal/dextran treated serum on expression and localization of alpha1D -adrenergic receptorSunil K Khattar, Roop Singh Bora, Priyanka Priyadarsiny, et al.Bioorganic & Medicinal Chemistry Letters|July 17, 2007
Synthesis and optimization of novel and selective muscarinic M(3) receptor antagonistsNaresh Kumar, Kirandeep Kaur, Shelly Aeron, et al.Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Design, synthesis and activity of novel derivatives of oxybutynin and tolterodineKirandeep Kaur, Shelly Aeron, Miriyala Bruhaspathy, et al.European Journal of Pharmacology|June 15, 2010
RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetesShuchita Singh, Subhasis Roy, Sachin Sethi, et al.Bioorganic & Medicinal Chemistry|February 28, 2017
Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A1 receptor antagonists and their biological evaluationSummon Koul, Vidya Ramdas, Dinesh A Barawkar, et al.Pageof 3